Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — Shareholder Meeting (November 2026)
27 slides from Atomo Diagnostics's shareholder meeting presentation, Nov 5, 2026
Slide 1: 2026 Annual General Meeting – MD & CEO's Address
For personal use only ASX Announcement 5 November 2026 2026 Annual General Meeting – MD & CEO’s Address In accordance with ASX Listing Rule 3.13.3, Atomo Diagnostics Limited (Atomo) attaches the MD & CEO’s Address to be delivered at Atomo’s 2026 Annual General Meeting. For more information, please c
Slide 2: FY26 AGM Presentation
rsonal use only ATOMO DIAGNOSTICS FY26 AGM PRESENTATION 5 NOVEMBER 2026 1
Slide 3: Disclaimer
DISCLAIMER ASX: AT1 This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on The information presented in this presentation is subject to change without notice and Atomo does rsonal use only information available as at the date of this presentation. The information in this
Slide 4: Purpose-led innovation built on core values
PURPOSE-LED INNOVATION BUILT ON CORE VALUES OUR PURPOSE: Empowering healthier lives through fast, accurate, point of care testing OUR MISSION rsonal use only Put the user experience at the centre of diagnostics—expanding equitable and affordable access to accurate diagnosis and a seamless pathway to
Slide 5: Who is Atomo and what do we do?
WHO IS ATOMO AND WHAT DO WE DO? Commercial-stage diagnostics company with a growing pipeline of proprietary and OEM partnerships WHO IS ATOMO? WHAT BUSINESSES DO WE HAVE? rsonal use only ATOMO PROPRIETARY PRODUCTS COMMERCIAL STAGE Blood-based rapid tests sold globally through professional and self-t
Slide 6: Solutions that deliver
SOLUTIONS THAT DELIVER Next generation POCT devices that provide superior usability and performance Initial solutions focused on transforming usability in the lateral flow market rsonal use only Issues with Standard Multi-Component Test Kits Advantages of Atomo Devices ATOMO DIAGNOSTICS LIMITED | (A
Slide 7: Atomo platform driving adoption of rapid testing
ATOMO PLATFORM DRIVING ADOPTION OF RAPID TESTING ASX: AT1 ASX: A1 Focus on ease of use, speed of results and affordability rsonal use only EASY TO USE Simple to use products providing reliability and usability in decentralised settings SPEED OF RESULTS Rapid results with a high degree of accuracy EA
Slide 8: Solutions that deliver: three blood-based platforms
SOLUTIONS THAT DELIVER Atomo offers three blood-based platforms driven by the market requirements Each platform simplifies capillary blood collection and delivery; the key difference is how it integrates with the test cassette. PASCAL GALILEO FLOREY rsonal use only Integrated all-in-one platform Str
Slide 9: Global quality & regulatory strength
GLOBAL QUALITY & REGULATORY STRENGTH ASX: AT1 ASX: A1 Atomo’s audited QMS supports registrations achieved directly and with partners QUALITY FOUNDATION GLOBAL REGULATORY FOOTPRINT External scrutiny rsonal use only Regularly audited by multiple tier-one national regulators and the World Health Organi
Slide 10: Two proven engines for commercial growth
TWO PROVEN ENGINES FOR COMMERCIAL GROWTH Commercial-stage diagnostics company pairing an established HIV franchise with a proven OEM platform Proven and growing revenue bases validate the two scalable paths to diversified growth rsonal use only ATOMO PROPRIETARY PRODUCT FRANCHISE OEM PARTNERSHIP BUS
Slide 11: Atomo proprietary product pipeline
ATOMO PROPRIETARY PRODUCT PIPELINE ASX: AT1 ASX: AT1 Commercial products fund a broader portfolio progressing through validation, development and feasibility rsonal use only PRODUCT / APPLICATION FEASIBILITY DEVELOPMENT VALIDATION COMMERCIAL STUDY HIV GEN 3 HIV screening / self-test COMMERCIAL ACTIV
Slide 12: Overview of Atomo's Gen 3 HIV self-test
OVERVIEW OF ATOMO'S GEN 3 HIV SELF-TEST ASX: AT1 Integrated, highly accurate self-testing platform with established market adoption and expanding retail and public-health channels TEST DIFFERENTIATION PRODUCT + MARKET PROOF rsonal use only 15 MINUTES 99.6% SENSITIVITY identifies HIV-positive samples
Slide 13: Active syphilis transfers to manufacturing
ACTIVE SYPHILIS TRANSFERS TO MANUFACTURING ASX: AT1 Program remains on schedule, with regulator engagement beginning and launch targeted within 18–24 months TEST DIFFERENTIATION EARLY CLINICAL PERFORMANCE rsonal use only 15 MINUTES 100% SENSITIVITY against active syphilis samples by clinical history
Slide 14: Gen 4 HIV partnership opens a new commercial path
GEN 4 HIV PARTNERSHIP OPENS A NEW COMMERCIAL PATH ASX: AT1 ASX: AT1 Global licence, development and supply agreement with Innovation Scientific WHO DOES WHAT COMMERCIAL PATH rsonal use only INNOVATION SCIENTIFIC 18 MONTHS THE MOU AGREEMENT — Complete final assay development Planned IVDR and TGA regi
Slide 15: ALT liver test: liver-injury insight at point of care
ALT LIVER TEST: LIVER-INJURY INSIGHT AT THE POINT OF CARE ASX: AT1 A proven ALT assay on Atomo’s Pascal platform creates multiple clinical, pharmaceutical and public-health pathways TEST PROPOSITION DEVELOPMENT + PERFORMANCE rsonal use only Development is substantially complete; ALT diagnostic perfo
Slide 16: OEM partner pipeline
OEM PARTNER PIPELINE ASX: AT1 ASX: AT1 Atomo technology enables partner assays to move from technical validation into commercial supply at scale PRODUCT / APPLICATION FEASIBILITY DEVELOPMENT VALIDATION COMMERCIAL rsonal use only FEBRIDX® Lumos · acute respiratory infection COMMERCIAL PREGNANCY NG Bi
Slide 17: FebriDx: fingerstick to 10-minute antibiotic decision aid
FEBRIDX®: FINGERSTICK TO 10-MINUTE ANTIBIOTIC DECISION AID ASX: AT1 ASX: AT1 Lumos’ CLIA-waived test combines dual host-response biomarkers with Atomo’s integrated Pascal platform RAPID RESPIRATORY TRIAGE PRODUCT + COMMERCIAL OVERVIEW rsonal use only FebriDx pairs Lumos’ MxA + CRP host-response assa
Slide 18: Pascal OEM revenue performance
PASCAL OEM REVENUE PERFORMANCE ASX: AT1 Strong YOY growth driven by Lumos Diagnostics’ FebriDx rsonal use only ATOMO OEM PERFORMANCE | FY26 YEAR-ON-YEAR US FEBRIDX® ADOPTION | LUMOS-REPORTED +209% +224% 215 LIVE US SITES September 2026 OEM SALES REVENUE GROWTH IN DEVICES SUPPLIED +26.5% 170 in July
Slide 19: Two blood-based tests expand Pascal platform
TWO BLOOD-BASED TESTS EXPAND PASCAL PLATFORM ASX: AT1 ASX: AT1 NG Biotech pregnancy and Chromacare ferritin programs pair partner assays with an integrated fingerstick NG BIOTECH | BLOOD PREGNANCY CHROMACARE | FERRITIN rsonal use only NG Biotech’s hCG assay and Atomo’s all-in-one Pascal Chromacare’s
Slide 20: Upfront + Atomo partner on next-generation test
UPFRONT + ATOMO PARTNER ON NEXT-GENERATION TEST ASX: AT1 ASX: AT1 Upfront’s biomarker assay moves into Atomo’s technology platform PARTNERSHIP ANNOUNCEMENT rsonal use only Atomo and Upfront announce partnership for Upfront’s next-generation test in Atomo’s device. DETECT DEPLOY DECIDE EARLIER LVTwo
Slide 21: FY 2026 Financials
rsonal use only FY 2026 FINANCIALS
Slide 22: FY26 – Profit & Loss
FY26 – PROFIT & LOSS Revenue grew strongly and the underlying EBITDA loss narrowed by 39% FY26 FY25 AUD (%) ($m) ($m) REVENUE rsonal use only Revenue 5.33 3.79 41% Cost of sales (3.45) (1.87) $5.33m FY25 $3.79m Gross Profit 1.88 1.92 (2%) +41% YoY Gross Margin 35% 51% GROSS MARGIN Other income 2.24
Slide 23: FY26 – Balance Sheet
FY26 – BALANCE SHEET FY26 closed with $3.71m in cash, $10.66m in assets and no bank debt FY26 FY25 AUD ($m) ($m) CASH rsonal use only Cash and cash equivalents 3.71 3.22 Trade and other receivables 3.22 1.69 $3.71m available liquidity Inventories 1.97 1.65 Property, plant and equipment 0.34 0.89 TOT
Slide 24: FY26 Cashflow
FY26 CASHFLOW Strong cash generation from sales, grants, and fundraising activities 16.00 TOTAL CASH RECEIPTS rsonal use only 14.00 $10.2m $4.6m customer receipts 12.00 plus R&D rebate, CRC-P grant and capital 10.00 TOTAL CASH PAYMENTS $9.7m A$m 8.00 $4.1m stock purchases 6.00 $5.6m operating expens
Slide 25: Financial Summary
FINANCIAL SUMMARY ASX: AT1 FY2026 was a transitional year, showing strong and sustainable revenue growth with improving EBITDA ✓ Atomo is seeing strong momentum in its established revenue ✓ Capital focus on new test portfolio channels including HIV Testing and Pascal OEM development / commercialisat
Slide 26: Strategic imperatives for FY2027
STRATEGIC IMPERATIVES FOR FY2027 Executing priorities focused on revenue growth, portfolio expansion, and scalable operations 01 HIV MARKET EXPANSION rsonal use only FY26 02 Grow established sales channels and secure new territory distribution partners. PORTFOLIO EXPANSION Scale the core. Advance fi
Slide 27: Building a stronger base for scalable growth
BUILDING A STRONGER BASE FOR SCALABLE GROWTH Commercial momentum is funding a broader product pipeline and a more diversified revenue base rsonal use only HIV FRANCHISE LEADS COMMERCIAL TRACTION $5.33m HIV sales increased 21% year on year, led by international supply and ANZ FY26 REVENUE | +41% YoY
Atomo Diagnostics — Shareholder Meeting (November 2026) on 6ix